Allergy Therapeutics Strong demand for “short course aluminium free allergy vaccines”

Allergy Therapeutics LON:AGY the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today gave DirectorsTalk a trading update covering the first four months of the 2016 financial year.

 

European demand for Allergy Therapeutics’ unique short course aluminium free allergy vaccines has continued to be strong since the year ended 30 June 2015. The Company’s like-for-like sales measured in constant currency increased by 12% in the Period compared with the same period in 2014. Including the Alerpharma acquisition completed in June 2015, constant currency sales increased 15% over the Period. Growth was notably strong in Germany, Austria, Netherlands and Spain and the Company continued to increase its market share during the Period.

 

Given the results are traditionally strongly weighted towards the first half of the Company’s financial year, the Board remains confident of strong results for the full year.

 

The Board also announces today that the Company has acquired the licence for Virus Like Particles (“VLP”), a new technology to be used in the treatment of peanut allergy, an $8bn p.a. addressable market globally. The Company intends to use the VLP licence in the development of Polyvac Peanut, a new injectable vaccine immunotherapy treatment for allergy sufferers, through to Phase I clinical trials. Polyvac Peanut represents the Company’s first move into products for treatment of food allergies and, to demonstrate the extent of the market opportunity, in the US alone, there are approximately 3 million people with peanut allergy and 100 – 150 attributable deaths each year. This therefore represents a significant and strategically important new area for the Group.

 

The Company also continues to progress a number of other opportunities in existing and new areas of immunotherapy treatment, including its programme to clinically develop Pollinex Quattro Grass through to FDA approval and subsequent launch in the US, anticipated for 2019. The Board believes that a combination of the Company’s strong product profile, positive sales momentum coupled with an ongoing disciplined investment in research and development will continue to win market share and accelerate growth in the current year and beyond. 

 

In light of the gathering momentum across all areas of the business, the Board will today also announce a placing to raise up to £12 million for the Company, to enable the Group to capitalise further on the incremental organic and inorganic growth opportunities available. 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Allergy therapeutics plc

More articles like this

Allergens dominate UK food recalls, finds study

More than half of food recalls in the United Kingdom over a 5-year period were due to allergens, according to a recently released study. Allergen-related recalls increased annually until 2019, peaking at 118 before decreasing to

Allergy Therapeutics welcomes new Non-Executive Directors

Allergy Therapeutics announced the appointments of Anthony Parker and Simon Shen to its Board as Non-Executive Directors effective immediately. “I would like to welcome Anthony and Simon. Southern Fox and ZQ Capital have been long-standing and supportive shareholders of Allergy

Allergy Therapeutics updates on its clinical programmes

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has announced that the first subject has been dosed in the pivotal Phase III G306 trial, to evaluate the efficacy and safety of

Allergy Therapeutics appoints two Non-Executive Directors

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has today announced the appointments of Anthony Parker and Zheqing (Simon) Shen as Non-Executive Directors of the Company, with immediate effect. Anthony represents

Allergies and Thanksgiving

As Thanksgiving and other holiday celebrations bring people around the table, Intermountain Healthcare dietitians say it’s crucial to take food allergies into consideration when planning the big meal. “A response to an allergic reaction can be

Allergy Therapeutics appoints Martin Hopcroft as interim CFO

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has announced the appointment of Martin Hopcroft to the role of Interim Chief Financial Officer (CFO). Martin will report into Chief Executive

Food business operator fined for allergy breach

A food business operator based in Newcastle, England has been fined in court after serving a dish containing peanuts to a woman with a peanut allergy, resulting in her being hospitalised. According to the Food Standards

Are restaurants taking allergies seriously?

In an engaging panel held at Twickenham Stadium as part of New Food’s Food Safety Conference 2022, experts came together to debate whether food allergy regulations in restaurants are sufficient. Here’s the highlights. Are restaurant allergy

Allergy Therapeutics Subscription to raise £7 million

Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical company specialising in allergy immunotherapy, today announces a conditional Subscription by the Subscribers, Southern Fox and ZQ Capital (acting through its affiliate SkyGem), to raise £7 million